These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19351063)

  • 1. [Obtaining and characteristics of domestic preparation interferon alpha-2b with prolonged effect].
    Pokholenko IaA; Porubleva LV; Dubeĭ IIa; Rebriev AV; Sutugina LP; Gromovoĭ TIu; Pokrovskiĭ VA; Obolenskaia MIu; Chernykh SI
    Ukr Biokhim Zh (1999); 2008; 80(6):92-100. PubMed ID: 19351063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
    Jo YW; Youn YS; Lee SH; Kim BM; Kang SH; Yoo M; Choi EC; Lee KC
    Int J Pharm; 2006 Feb; 309(1-2):87-93. PubMed ID: 16406701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interferon alpha-2b modified with polyethylene glycol].
    Wu Y; Zhai Y; Lei J; Ma G; Su Z
    Sheng Wu Gong Cheng Xue Bao; 2008 Sep; 24(9):1658-63. PubMed ID: 19160853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and biologic characterization of pegylated recombinant IFN-alpha2b.
    Grace M; Youngster S; Gitlin G; Sydor W; Xie L; Westreich L; Jacobs S; Brassard D; Bausch J; Bordens R
    J Interferon Cytokine Res; 2001 Dec; 21(12):1103-15. PubMed ID: 11798469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convenient biological assay for polyethylene glycol-interferons in patients with hepatitis C.
    Boulestin A; Kamar N; Legrand-Abravanel F; Sandres-Saune K; Alric L; Vinel JP; Rostaing L; Izopet J
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3610-2. PubMed ID: 15328140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Site-Specific Transglutaminase-Mediated Conjugation of Interferon α-2b at Glutamine or Lysine Residues.
    Spolaore B; Raboni S; Satwekar AA; Grigoletto A; Mero A; Montagner IM; Rosato A; Pasut G; Fontana A
    Bioconjug Chem; 2016 Nov; 27(11):2695-2706. PubMed ID: 27731976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEG-interferon conjugates: effects of length and structure of linker.
    Sabar MF; Kausar S; Zafar AU
    Pak J Pharm Sci; 2013 Mar; 26(2):425-30. PubMed ID: 23455218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity.
    Monkarsh SP; Ma Y; Aglione A; Bailon P; Ciolek D; DeBarbieri B; Graves MC; Hollfelder K; Michel H; Palleroni A; Porter JE; Russoman E; Roy S; Pan YC
    Anal Biochem; 1997 May; 247(2):434-40. PubMed ID: 9177709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multivesicular liposome formulations for the sustained delivery of interferon alpha-2b.
    Qiu J; Wei XH; Geng F; Liu R; Zhang JW; Xu YH
    Acta Pharmacol Sin; 2005 Nov; 26(11):1395-401. PubMed ID: 16225764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).
    Reddy KR
    Semin Liver Dis; 2004; 24 Suppl 2():33-8. PubMed ID: 15346244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of pegylated interferon-alpha-2a or -2b does not induce sickness behavior in Lewis rats.
    Loftis JM; Wall JM; Pagel RL; Hauser P
    Psychoneuroendocrinology; 2006 Nov; 31(10):1289-94. PubMed ID: 17049181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS).
    Foser S; Schacher A; Weyer KA; Brugger D; Dietel E; Marti S; Schreitmüller T
    Protein Expr Purif; 2003 Jul; 30(1):78-87. PubMed ID: 12821324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.
    Rosendahl MS; Doherty DH; Smith DJ; Carlson SJ; Chlipala EA; Cox GN
    Bioconjug Chem; 2005; 16(1):200-7. PubMed ID: 15656592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
    García-García I; González-Delgado CA; Valenzuela-Silva CM; Díaz-Machado A; Cruz-Díaz M; Nodarse-Cuní H; Pérez-Pérez O; Bermúdez-Badell CH; Ferrero-Bibilonia J; Páez-Meireles R; Bello-Rivero I; Castro-Odio FR; López-Saura PA;
    BMC Pharmacol; 2010 Nov; 10():15. PubMed ID: 21092287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.
    Asahina Y; Izumi N; Umeda N; Hosokawa T; Ueda K; Doi F; Tsuchiya K; Nakanishi H; Matsunaga K; Kitamura T; Kurosaki M; Uchihara M; Higaki M; Miyake S
    J Viral Hepat; 2007 Jun; 14(6):396-403. PubMed ID: 17501760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway.
    Grace MJ; Lee S; Bradshaw S; Chapman J; Spond J; Cox S; Delorenzo M; Brassard D; Wylie D; Cannon-Carlson S; Cullen C; Indelicato S; Voloch M; Bordens R
    J Biol Chem; 2005 Feb; 280(8):6327-36. PubMed ID: 15596441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and characterization of magnetic microspheres for the purification of interferon alpha-2b.
    Cao Y; Bai G; Chen J; Tian W; Wang S; Yang W
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Apr; 833(2):236-44. PubMed ID: 16490407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylation of IFN-alpha and antiviral activity.
    Boulestin A; Kamar N; Sandres-Sauné K; Alric L; Vinel JP; Rostaing L; Izopet J
    J Interferon Cytokine Res; 2006 Dec; 26(12):849-53. PubMed ID: 17238827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load.
    Izumi N; Asahina Y; Kurosaki M; Uchihara M; Nishimura Y; Inoue K; Ueda K; Tsuchiya K; Hamano K; Itakura J; Miyake S
    Intervirology; 2004; 47(2):102-7. PubMed ID: 15192274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis.
    Sporea I; Danila M; Sirli R; Popescu A; Laza A; Baditoiu L
    J Gastrointestin Liver Dis; 2006 Jun; 15(2):125-30. PubMed ID: 16802006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.